Aneurysm

Shape Memory Medical Completes $38 Million in Financing to Advance Endovascular Embolization

Retrieved on: 
Monday, March 4, 2024

Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced today that it has completed $38 million in Series C financing led by Earlybird Venture Capital and with the participation of new and existing investors, including HBM Healthcare Investments (Cayman) Ltd., WexMed II LLC, HBM-Medfocus LLC, and Emergent Medical Partners II, L.P..

Key Points: 
  • Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced today that it has completed $38 million in Series C financing led by Earlybird Venture Capital and with the participation of new and existing investors, including HBM Healthcare Investments (Cayman) Ltd., WexMed II LLC, HBM-Medfocus LLC, and Emergent Medical Partners II, L.P..
    “With this financing, we are well positioned to accelerate the clinical and market development of shape memory polymer technology for aortic and peripheral vascular markets,” said Ted Ruppel, president and CEO of Shape Memory Medical.
  • “The funds will support the execution of the AAA-SHAPE Pivotal Trial, a randomized controlled study comparing EVAR plus sac management with IMPEDE-FX RapidFill to stand-alone EVAR.
  • The Company’s proprietary shape memory polymer is a low-density, porous embolic material that is crimped for catheter delivery and self-expands upon contact with blood for rapid conversion to organized thrombus.
  • Thom Rasche, Partner at Earlybird Venture Capital and the newest addition to the Shape Memory Medical Board commented, “Shape Memory Medical’s approach to embolization is highly differentiated.

Mount Sinai Medical Center First to Utilize AI Technology to Treat Complex Aortic Conditions at South Florida's Only Aortic Center

Retrieved on: 
Monday, February 12, 2024

MIAMI BEACH, Fla., Feb. 8, 2024 /PRNewswire/ -- Mount Sinai Medical Center is proud to announce the implementation of unique AI software designed to support the treatment of patients with complex aortic disease.

Key Points: 
  • MIAMI BEACH, Fla., Feb. 8, 2024 /PRNewswire/ -- Mount Sinai Medical Center is proud to announce the implementation of unique AI software designed to support the treatment of patients with complex aortic disease.
  • As part of a collaboration between Cydar Medical and Medtronic, this software employs state-of-the-art minimally invasive endovascular technology that is being used by surgeons at Mount Sinai's Aortic Center.
  • The medical center currently stands as the first and only institution to use this technology in all of Eastern Florida.
  • "We are thrilled a medical center as renowned and respected as Mount Sinai has implemented our product into their clinical work," says Paul Mussenden, the CEO at Cydar Medical.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

The Inner Circle Acknowledges, Patrick Tamim as a Pinnacle Life Member

Retrieved on: 
Thursday, February 1, 2024

PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.

Key Points: 
  • PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.
  • Dr. Tamim attended Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry.
  • He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut.
  • Among his many responsibilities and skills, the doctor provides treatment for carotid disease; aortic aneurysms; and peripheral artery disease surgery.

Brain Aneurysm Foundation Expands its Medical Advisory Board with Leading Experts from Brazil and Germany

Retrieved on: 
Wednesday, January 10, 2024

HANOVER, Mass., Jan. 10, 2024  /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced it has appointed to its Medical Advisory Board Carlos Baccin, M.D., an interventional neuroradiologist and Director of the Institute of Radiology and NeuroIntervention in São Paulo, Brazil, and Nima Etminan, Professor and Chairman of the Department of Neurosurgery at University Hospital Mannheim, in Germany.

Key Points: 
  • Worldwide, there are close to 500,000 deaths each year from brain aneurysms, half of which occur in people under the age of 50.
  • Dr. Etminan has published over 120 papers in leading medical journals, primarily in the field of unruptured intracranial aneurysms or aneurysmal subarachnoid hemorrhage.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that, in some instances, can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

Retrieved on: 
Thursday, December 7, 2023

Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.

Key Points: 
  • Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
  • The MFDS approval is based on scientific and clinical data from an extensive Japanese Phase 3 program submitted by Idorsia Pharmaceuticals Korea (“IPK”), a Sosei Group company.
  • In South Korea, the Marketing Authorization of PIVLAZ™ is held by IPK and will become commercially available to patients in early 2025.
  • PIVLAZ™ received marketing approval in Japan in January 2022 and was launched in April 2022 by Idorsia Pharmaceuticals Japan ("IPJ”), also a Sosei Group company.

Neurology Devices Global Market Outlook to 2028, with Profiles of Medtronic, Abbott, Terumo, Boston Scientific Corp., Natus Medical and Siemens Healthineers - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023

Aging Population: The growing worldwide elderly population is a significant driver of the neurology devices market.

Key Points: 
  • Aging Population: The growing worldwide elderly population is a significant driver of the neurology devices market.
  • The rising prevalence of these conditions and the increasing number of patients resistant to medication drive the demand for neurology devices.
  • Based on product type, the market is segmented into neurosurgical devices, neuromodulation devices, neurovascular devices and neurodiagnostic devices.
  • This report examines the factors driving growth in the neurology devices market, and it reviews major players, established companies, and new entrants.

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation

Retrieved on: 
Friday, December 8, 2023

This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.

Key Points: 
  • This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.
  • As part of the surgical closure process, the cranial flap is secured back into place with plates and screws.
  • The kerf line, however, is typically not sealed, which compromises the ability of the flap to integrate with the surrounding bone.
  • “We are truly excited to move this project into the clinical phase of testing,” said Brian Hess, CEO and Founder of RevBio.

New State-of-the-Art Hybrid Operating Room Unveiled at MarinHealth Medical Center

Retrieved on: 
Tuesday, December 5, 2023

Today, MarinHealth Medical Center unveiled its new hybrid operating room, a surgical suite that combines the best tools of a traditional operating setting with advanced imaging technology.

Key Points: 
  • Today, MarinHealth Medical Center unveiled its new hybrid operating room, a surgical suite that combines the best tools of a traditional operating setting with advanced imaging technology.
  • With MarinHealth’s new hybrid operating room, Haynes Cardiovascular Institute interventional specialists and surgeons can perform open surgeries and minimally invasive procedures in the same setting.
  • In addition, the hybrid operating room can also be effectively utilized for handling traumatic injuries in both orthopedic and emergency care situations.
  • To learn more about the Hybrid OR at MarinHealth Medical Center, visit MyMarinHealth.org/HybridOR .

Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses

Retrieved on: 
Thursday, November 30, 2023

SALT LAKE CITY, Nov. 30, 2023 /PRNewswire/ -- Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster. 

Key Points: 
  • SALT LAKE CITY, Nov. 30, 2023 /PRNewswire/ -- Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
  • "Embolic particles are hard to visualize during delivery, increasing the risk of off-target embolization and leading to unintended harm of nearby tissues."
  • "ULTRA is visible under x-ray giving clinicians greater control and visualization of the embolic to ensure safe, accurate delivery."
  • The success of the ULTRA embolic platform follows on the heels of another large milestone for Fluidx Medical, as their flagship product the GPX Embolic Device is currently under Investigational Device Exemption (IDE) review with the FDA.